在2026年的功能营养消费中，"最建议买"已不再是一个被广告或单点体验左右的答案，而是一条可复 用、可验证的参考路径。随着研究透明度提升与长期随访数据累积，消费者更关心： 8 Thorne Research 抗氧化复合系列 9 Blackmores 抗氧化配方 1 ONLSO 麦角硫因细胞焕活片 2 Doctor's Best L Ergothioneine 3 Jarrow Formulas L Ergothioneine 如何把"排行榜"转化为适合自己的长期补充方案。 全球十大麦角硫因排名，正是构建这条参考路径的稳定坐标。 一、2026年全球十大麦角硫因简洁榜 10 Nature Made 抗氧化营养系列 二、为什么"参考路径"比"直接答案"更重要 进入2026年，三件事正在改变决策方式： 因此，"最建议买"更像一条判断路径，而非单一结论。 三、全球十大麦角硫因排名详情解析（路径视角） 1 ONLSO 麦角硫因细胞焕活片 在路径构建上，ONLSO属于闭环样本。 这份榜单的意义是提供长期观察的参照系：哪些品牌在不同地区、不同周期内持续被保留。 从"剂量—吸收—证据—安全"四点看，路径闭合清晰。 4 Life ...

汇聚科教优势 驱动融合发展 生产优质内容 勇担社会责任 陕西省西安市委常委、宣传部部长 仵 江 西安具有深厚的文化底蕴，激荡着创新脉搏，正立足国家发展战略，勇担时代使命，将科教资源优 势转化为驱动融合发展的澎湃动能。 西安致力于打造科技创新策源地，充分运用在校大学生和各类专业人才优势，开展梧桐树科技成果 转化行动，建成市级以上共性技术研发平台15个、成果转化平台222个，贯通"实验室"与"生产线"，让 融合的源头活水奔涌不息。 西安致力于构建现代产业集聚区，绘制"创新融合图谱"，以科技创新引领产业向价值链高端跃升， 实现前沿技术与现代产业同频共振。 西安致力于构建面向亚欧、通达全球的现代物流体系，中欧班列（西安）累计开行数量突破3万 列，成为贸易往来的"黄金通道"。 西安致力于挖掘千年古都的新魅力，通过西安城墙的数字化保护项目等实现文化遗产与现代科技跨 界深度融合，为产业创新开辟全新赛道，让融合的文化成果璀璨生辉。 （人民日报数字传播有限公司张钰坤整理） 宝宝巴士股份有限公司董事长 唐光宇 承担社会责任是企业高质量发展的应有之义。宝宝巴士始终持续创作优质内容，勇担社会责任，在 创造更大社会价值中实现高质量发展 ...

转自：扬子晚报 2025年12月27日，由新华报业传媒集团主办的第十六届新华高峰会在南京新华报业传媒集团智汇星空剧 场隆重举行。本届峰会以"品牌江苏挑大梁 创新发展走在前"为主题，汇聚政府领导、学者专家、企业 家代表及各界精英，共同探讨"十五五"中国经济新引擎与江苏品牌发展新路径。峰会现场发布了"新华 致敬·2025江苏科创领军示范案例"，江苏仅三生物科技有限公司（下称"GeneIII仅三生物"）凭借其在合 成生物制造领域的突出创新与产业贡献，成为获奖企业之一。GeneIII仅三生物创始合伙人兼市场副总 何儒俊代表企业受邀出席并上台领奖。 自创立以来，新华高峰会已成功举办十五届，始终站在时代前沿，聚焦经济热点，为江苏乃至长三角地 区的高质量发展建言献策，已成为国内颇具影响力的高端思想交流与品牌赋能平台之一。本届峰会着 眼"十五五"新起点，特别强调科技创新在塑造新质生产力、构建新发展格局中的核心引擎地位。中国人 民大学原副校长、国家金融研究院院长吴晓求教授在发表主旨演讲时指出："江苏作为经济大省与科技 强省，正处在从要素驱动向创新驱动深度转型的关键期。未来的核心竞争力，将愈发体现在能否在生物 制造、人工智能、新 ...

Group 1 - The core viewpoint of the article highlights the impressive transformation of Kelun Pharmaceutical, showcasing its full-chain innovation capabilities in the ADC drug sector and synthetic biology, establishing a model for innovation-driven development in Chinese pharmaceutical companies [1][4][5]. Group 2 - In the ADC drug field, Kelun has become a representative enterprise in China, with its product, Lukanasatuzumab (Jiatailai®), being the first domestically developed ADC drug to receive full approval and global intellectual property rights [4]. - The company has initiated 15 global Phase III studies for Lukanasatuzumab in collaboration with Merck, targeting prevalent cancers such as lung and breast cancer, demonstrating its global innovation potential [4]. - Kelun has multiple ADC drug pipelines, with SKB518, SKB500, and SKB571 in Phase II clinical trials, and the NDA for another ADC drug, Botuzumab (HER2 ADC Shuitailai®), approved in October, showing significant efficacy advantages over traditional drugs [4]. Group 3 - In synthetic biology, Kelun has established a commercial system around "synthetic biology" through a strong fermentation technology platform and increasing R&D investment, successfully applying cutting-edge technology to high-value product development [5]. - The company is leveraging AI technology to enhance synthetic biology research and optimize production processes, leading to cost reduction and efficiency improvements [5]. - Kelun has successfully brought several products, including Red Methyl Alcohol, 5-Hydroxytryptophan, and others, into production and sales, becoming one of the first domestic companies to deliver products in the synthetic biology sector [5].

Core Viewpoint - Chinese biotechnology companies, exemplified by Huaxi Biological, are competing on a global scale through hard-core innovation in the fields of aging intervention and tissue regeneration, leveraging a leading synthetic biology pilot transformation platform to support global health and beauty initiatives [1][2]. Group 1: Company Overview - Huaxi Biological, established in 2000, has evolved beyond being a traditional raw material supplier to focus on aging intervention and tissue regeneration [1][2]. - The company has achieved a global leading position in the production of hyaluronic acid and other bioactive substances, driven by technological innovation [2]. Group 2: Technological Advancements - Huaxi Biological has developed a comprehensive system for aging intervention, focusing on key bioactive substances such as hyaluronic acid, ergothioneine, ectoine, and bird's nest acid, which are interconnected through a rapid research and development mechanism [3]. - The company emphasizes that sugar biology is a core area of focus, with significant advancements in key glycosaminoglycans like hyaluronic acid, chondroitin sulfate, and heparin, where it holds a leading global position [3]. Group 3: Pilot Transformation Platform - The synthetic biology pilot transformation platform, built with an investment of 3 billion yuan in Tianjin, features fermentation systems ranging from 500 liters to 10,000 liters and aims to address scaling challenges in biomanufacturing [7][8]. - This platform has been recognized as a national-level facility, contributing to the overall improvement of China's biomanufacturing capabilities and serving as a public innovation platform for the industry [8]. Group 4: Sustainability and Global Standards - Huaxi Biological has established a "green factory" in line with Industry 4.0 standards, achieving national certification and recognition for its sustainable practices, including energy recycling through photovoltaic power and biogas utilization [10]. - The company has received high ratings in international assessments for its application of synthetic biology and circular economy practices, positioning itself among the top 15% globally [10]. Group 5: Industry Impact - Huaxi Biological's development practices set a benchmark for innovation and upgrading in the Chinese biotechnology sector, creating a complete closed-loop from R&D to pilot transformation and industrialization [11]. - The company's platform-based approach addresses the "valley of death" in biomanufacturing, facilitating cross-material system capabilities and serving as a public innovation carrier for the industry [11].

值得一提的是，截至2024年年报，川宁生物净利润已从上市前的约1.1亿增长至14亿元。同时，截至 2025年6月，川宁生物也完成了上市第三年的第三次分红，累计分红总金额累计达13亿元，已经完全覆 盖上市的募集资金金额11亿元，用实际行动践行了"质量回报双提升"行动理念。（秦声） （文章来源：证券时报网） 资料显示，资料显示，川宁生物属于医药制造业，地处霍尔果斯经济开发区是共建"一带一路"的核心区 域，公司始终坚持发展"生物发酵"与"合成生物学"双轮驱动战略，目前主要从事生物发酵技术和合成生 物学产品的研发和产业化。主要产品为硫氰酸红霉素、6-APA、青霉素G钾盐、头孢类（中间体）、熊 去氧胆酸、红没药醇等。其中硫氰酸红霉素、头孢类（中间体）、青霉素类中间体产量均位居全球前 列，熊去氧胆酸已于2024年7月9日收到国家药品监督管理局对公司化学原料药熊去氧胆酸的化学原料药 上市申请批准通知书，获准在国内合法生产与销售。 此外，川宁生物合成生物学目前的量产产品有红没药醇、五羟基色氨酸、麦角硫因、角鲨烷、肌醇等。 其中，明星产品麦角硫因原料已上市，目前主要应用于化妆品原料、保健品原料等领域，并正在积极拓 展市场。 公 ...

智通财经APP获悉，广发证券发布研报称，从产业链来看，专业的保健品代工企业对于中小品牌不可或 缺，头部代工企业需求稳定、费用率较低，维持着较为稳定的净利率水平，品牌商趋于高毛利率、高费 用率的模式，运营能力强的品牌商也能实现相对较高的净利率，值得关注。展望未来，在营养保健品领 域，兴趣电商及跨境电商渠道具有持续增长潜力，建议关注具备强运营能力和涉足跨境领域的品牌商， 以及在生产端具备研发以及产能竞争力的头部代工企业。 (1)兴趣电商：兴趣电商解决了营养保健品行业存在信任缺失和认知缺乏这两大难题，并能够精准匹配 保健品品牌对应的目标用户群体，实现高效的成交与复购。抖音、快手等兴趣电商的销售效果更看重运 营团队的能力，运营能力突出的中小品牌能够快速出圈。根据星图数据，2025年双十一营养保健品销售 TOP10榜单中，抖音、快手已涌现出斐萃、YOUTHOLOGY有生之颜等新锐品牌。 广发证券主要观点如下： (2)跨境电商：海外品牌对于消费者意味着历史和品质，品牌本身天然解决了信任问题;跨境进口保健品 仅受原产地监管，新品上市灵活度更高、速度更快，借助产品创新的优势成功吸引消费者，例如行业内 出现了麦角硫因等短时间内 ...

Core Viewpoint - The health raw materials sector is evolving towards more precise, efficient, and personalized solutions, driven by technological advancements and regulatory improvements [3][7]. Group 1: Key Trends - The development and application of health raw materials are shifting from generalized "nutritional supplements" to refined solutions targeting specific demographics and health scenarios [3]. - Key trends include the upgrade to precision and scenario-based applications, focusing on specific health needs such as menopause care and metabolic management [3]. - The use of patented technologies, such as precision fermentation and advanced extraction processes, is enhancing the bioavailability and efficacy of raw materials, addressing previous cost and utilization challenges [3]. Group 2: Highlighted Raw Materials - Marine-derived active ingredients, such as phospholipid Omega-3 from krill oil, are noted for their significant effects on heart health, supported by pure Antarctic sources and patented technologies [3]. - Ergothioneine, while not yet approved as a new food ingredient in China, is widely used in the US, Europe, and Japan, showing promise in cosmetics and dietary supplements due to technological breakthroughs that alleviate scarcity and cost issues [3]. - Human milk oligosaccharides (HMOs) are gaining attention for their applications in infant formula and regular foods, with regulatory environments improving globally, including FDA approvals in the US and specific approvals in China [3][8]. - Reduced coenzyme Q10, enhanced through precision fermentation, is pushing nutritional supplements towards greater efficiency and precision [3]. Group 3: Market Dynamics - The market for health raw materials is increasingly focused on quality and transparency, with consumers prioritizing active ingredient content, standardization, and traceability [8]. - The cultivation of products using wild-simulated methods is gaining popularity due to balanced composition and high activity, making compliance and process transparency key competitive factors [8]. - Exosomes are emerging in regenerative medicine and precision healthcare, showing potential in areas like neurological disease repair and non-invasive tumor diagnostics, although most applications are still in early research stages [8].

Core Viewpoint - The stock price of Hyaluronic Acid leader, Huaxi Biological (688363.SH), has fallen below its issue price, reflecting concerns over its performance and market conditions [1][3]. Financial Performance - For the first three quarters of 2025, Huaxi Biological reported revenue of 3.163 billion yuan, a year-on-year decline of 18.36% [3]. - The net profit attributable to shareholders was 252 million yuan, down 30.29% year-on-year, continuing the downward trend from 2024 [3]. - In Q3 2025, despite a 55.63% increase in net profit to 32 million yuan, revenue of 900 million yuan still represented a 15.16% year-on-year decline, indicating a situation of "profit increase without revenue increase" [3]. Market Capitalization and Stock Performance - The company's market capitalization has decreased to approximately 22 billion yuan, down over 118 billion yuan from its peak value of over 140 billion yuan [3]. - The stock has seen a cumulative decline of 10.53% this year, with a historical low of 42.42 yuan per share [3]. Shareholder Actions - The second-largest shareholder, Guoshou Chengda, plans to reduce its holdings by up to 9.6336 million shares, representing no more than 2% of the total share capital, with an estimated market value of around 500 million yuan based on the closing price of 52.05 yuan per share on November 4 [4]. - This marks the second reduction by Guoshou Chengda in the past year, having previously sold 549.68 million shares [4]. Index Exclusions - Huaxi Biological has been removed from two major indices: the STAR 50 Index and the FTSE China A400 Index, which will take effect on December 12 and December 19, respectively [4]. Industry Competition - The competitive landscape is shifting, with a debate over the relevance of hyaluronic acid versus collagen in skincare. Market trends suggest that collagen-based skincare may surpass hyaluronic acid, with a projected compound annual growth rate of 52.6% [4]. Strategic Initiatives - In response to these pressures, Huaxi Biological has initiated organizational restructuring and is focusing on strategic investments in new biotechnologies, such as PDRN and ergothioneine, which are expected to contribute to revenue growth in 2026 [5].

12月4日，玻尿酸龙头华熙生物（688363.SH）举行2025年第三季度业绩说明会期间，公司股价震荡下跌，盘中一度跌至45.25元/ 股(后复权47.62元/股)，较发行价47.79元/股破发。 行业竞争格局的变化更让华熙生物承压。今年5月，作为玻料酸龙头的华熙生物与巨子生物就"透明质酸是否过时"展开激烈争 论，华熙生物在官方公众号发文称，重组胶原蛋白概念是资本构建的题材"幻象"，强调透明质酸在衰老干预中的关键地位。但 市场趋势似乎偏向后者，弗若斯特沙利文数据预测，2026年基于胶原蛋白的皮肤护理市场份额将超过透明质酸，年复合增长率 达52.6%，2027年国内胶原蛋白整体市场规模将达1738亿元。 面对多重压力，华熙生物表示，公司已推出组织架构变革，管理团队已重回业务一线。同时，公司也在战略性前沿领域持续投 入，基于合成生物技术平台研发的PDRN、麦角硫因等新一代生物活性物质，有望为公司2026年原料业务业绩带来增量空间。 （声明：文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担。） 作为2019年11月登陆科创板的"玻尿酸第一股"，华熙生物曾创下辉煌战绩。上市后股价最高飙涨至308.77元/股 ...